drugset / Trial / NCT03939871
A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center phase II study designed to evaluated the efficacy and safety of fulvestrant in combination with oral vinorelbine in hormone receptor-positive advanced breast cancer
Timeline
- Start
- 2017-12-12
- Primary completion
- 2020-12-12
- Completion
- 2020-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vinorelbine | Small molecule | 60 mg/kg | Oral |
| Subject | fluvestrant | Unknown | 0.5 g | Intramuscular |